March 4, 2026 · Form 4 insider transaction
Shields Matthew bought 33,424 shares of Teva Pharmaceutical Industries Limited at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.; Restricted share units were granted on March 4, 2026, with 8,356 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029, and March 4, 2030.; The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.